Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 343 across all filing types
Latest filing 2025-12-15 Major Shareholding Noti…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is a formal 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds) issued by the AMF (Autorité des marchés financiers). It details that Seventure Partners has crossed below the 15% threshold of capital and voting rights in MAAT PHARMA. This is a standard regulatory notification regarding significant shareholding changes, which corresponds to the 'Major Shareholding Notification' category.
2025-12-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by MaaT Pharma announcing the presentation of clinical trial results (ARES Phase 3) at a medical congress (ASH 2025). It details efficacy data, patient profiles, and survival rates for their drug candidate MaaT013. This type of announcement, which provides updates on clinical trial progress and results, is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding company operations and clinical milestones that does not fit into more specific categories like 'Earnings Release' or 'Investor Presentation'.
2025-12-08 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from MaaT Pharma announcing clinical trial results (Phase 3 ARES study) for their drug candidate MaaT013. It details efficacy data, patient profiles, and survival rates presented at a medical congress (ASH 2025). This is a standard corporate announcement of clinical trial results, which falls under the 'Earnings Release' category in the context of biotech/pharma companies reporting key performance/clinical milestones, or more broadly as a regulatory/corporate announcement. Given the specific definitions provided, this is a corporate announcement of clinical results, which is best classified as an Earnings Release (ER) in the context of biotech reporting, or a Regulatory Filing (RNS) if strictly interpreted. However, since it reports on the primary business outcome (clinical trial success), ER is the most appropriate fit for a biotech company's milestone announcement. FY 2025
2025-12-08 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is a formal 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds) issued by the AMF (Autorité des marchés financiers). It explicitly states that a specific entity (Invus Public Equities, L.P.) has crossed the 5% threshold of capital and voting rights in the company MAAT PHARMA. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-11-21 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the successful completion of a capital increase (Global Offering) by MaaT Pharma. It details the number of shares issued, the price per share, the use of proceeds, the impact on share capital, and the involvement of institutional investors. This falls under the category of capital raising and financing activities, which is specifically defined as 'CAP' (Capital/Financing Update).
2025-11-14 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Capital/Financing Update Classification · 100% confidence The document is a press release from MaaT Pharma announcing the successful completion of a capital increase (Global Offering) of 9.1 million euros. It details the number of shares issued, the price per share, the use of proceeds, the impact on shareholding structure, and the resumption of trading on Euronext Paris. This falls under the category of capital raising and financing activities.
2025-11-14 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.